MedTrace Logo

Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment

NCT04751084 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 675

Last updated 2024-05-08

No results posted yet for this study

Summary

To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high uterine contraction frequency prior to embryo transfer has a higher live birth rate.

Conditions

  • IVF
  • Intracytoplasmic Sperm Injection

Interventions

DRUG

Buscopan 20 milligrams/ML Injectable Solution

cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • SZE MAN JENNIFER MAK · Chinese University of Hong Kong

  • NGA PING PATRICIA IP · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2024-04-30
Completion
2024-09-14

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04751084 on ClinicalTrials.gov